Sarepta Therapeutics (NASDAQ:SRPT) Earns “Market Perform” Rating from William Blair

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “market perform” rating reaffirmed by equities research analysts at William Blair in a research note issued to investors on Friday, MarketBeat.com reports.

Other research analysts have also issued reports about the stock. HC Wainwright lowered shares of Sarepta Therapeutics from a “neutral” rating to a “sell” rating in a research note on Monday, June 16th. Scotiabank upgraded shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target on the stock in a research report on Friday, June 6th. UBS Group decreased their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Jefferies Financial Group decreased their price target on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating on the stock in a research report on Monday, June 16th. Finally, Bank of America restated a “neutral” rating and issued a $28.00 price target (down from $76.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and an average target price of $67.64.

Sarepta Therapeutics Stock Down 3.3%

Sarepta Therapeutics stock opened at $20.08 on Friday. The company has a market capitalization of $1.97 billion, a P/E ratio of -7.46 and a beta of 0.61. The firm’s fifty day simple moving average is $43.10 and its 200-day simple moving average is $82.59. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a 1-year low of $18.30 and a 1-year high of $168.31.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 EPS. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently made changes to their positions in the company. EP Wealth Advisors LLC increased its position in shares of Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after buying an additional 105 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Sarepta Therapeutics by 5.1% in the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 139 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 145 shares in the last quarter. Virtus ETF Advisers LLC increased its position in shares of Sarepta Therapeutics by 6.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 174 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.